**Core Concept**
Malignant hyperthermia (MH) is a life-threatening medical emergency triggered by certain anesthetic agents, particularly volatile anesthetics and succinylcholine. This condition is characterized by a hypermetabolic state, leading to excessive heat production, muscle rigidity, and potentially fatal complications.

**Why the Correct Answer is Right**
Malignant hyperthermia is primarily caused by mutations in the ryanodine receptor type 1 (RyR1) gene, which codes for a calcium channel in skeletal muscle cells. When exposed to triggering agents, these mutated receptors are activated, leading to an abnormal release of calcium ions from the sarcoplasmic reticulum. This uncontrolled calcium influx causes sustained muscle contractions, leading to the characteristic symptoms of MH.

**Why Each Wrong Option is Incorrect**
**Option A:** This option is incorrect because malignant hyperthermia is not primarily caused by an imbalance of electrolytes or a defect in the muscle's excitation-contraction coupling mechanism, although these factors may contribute to the condition's severity.
**Option B:** This option is incorrect because malignant hyperthermia is not directly related to a deficiency in the enzyme acetylcholinesterase, which breaks down acetylcholine in the neuromuscular junction.
**Option C:** This option is incorrect because malignant hyperthermia is not primarily caused by a genetic defect in the myostatin gene, which regulates muscle growth and development.

**Clinical Pearl / High-Yield Fact**
Malignant hyperthermia can be triggered by a variety of anesthetic agents, including halothane, isoflurane, sevoflurane, and desflurane, as well as the depolarizing muscle relaxant succinylcholine. It is essential to have a high index of suspicion and promptly identify patients at risk, such as those with a family history of MH or a known genetic mutation.

**Correct Answer:** D.